Sensyne Health signs deal with UK government for pilot study with lateral flow tests

Sensyne Health the British Clinical AI technology company, on Friday announced it has signed a £470,000 agreement with the Department of Health & Social Care to conduct the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests.

252

Agreement with the UK Department of Health & Social Care to pilot Sensyne Health’s MagnifEye™ technology for use with COVID-19 lateral flow diagnostic tests

Oxford, U.K. 12 March 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the British Clinical AI technology company, today announces it has signed a £470,000 agreement with the Department of Health & Social Care to conduct the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests.

The agreement with the Department of Health & Social Care follows an announcement made by Sensyne on 09 February 2021 that it had signed an exclusive licence and development agreement with Excalibur Healthcare Services Limited to apply MagnifEye for use with lateral flow rapid diagnostic tests.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: 

“We are delighted to be working with the Department of Health & Social Care and Excalibur and are happy to be able to contribute to the UK’s COVID-19 testing programme by providing our MagnifEye technology for use with lateral flow diagnostic tests and look forward to the results of this pilot study.”

Also earlier this month:

Syne-COV COVID prediction algorithm achieves UKCA mark status

First of a number of clinical AI algorithms being developed on the Company’s SENSE clinical and operational algorithm engine.

SYNE-COV product was developed in collaboration with Chelsea & Westminster Hospitals NHS Foundation Trust and will now be offered to NHS Trusts across the UK.

Oxford, U.K. 01 March 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the“Group”), the UK Clinical AI company, today announces that its SYNE-COV™ machine learning algorithm for COVID risk prediction has achieved UKCA mark status for use in the UK.

About SYNE-COV

SYNE-COV analyses over 60 variables in the patient electronic health record to generate a prediction of the likelihood of a COVID positive patient developing severe disease, requiring ventilation or admission to intensive care. It provides the risk prediction, together with an explanation of the result, to help clinicians manage patients admitted to hospital with COVID infection.  

The SYNE-COV product was developed in collaboration between Sensyne and the Chelsea & Westminster Hospitals NHS Foundation Trust This is the first algorithm developed from the SENSE™ clinical and operational algorithm engine to achieve UKCA mark status.  SENSE generates Clinical AI algorithms (called SYNEs) from the analysis of data in patient electronic health records to provide decision support to clinicians. The Company has several algorithms currently in development across multiple medical conditions, which subject to achieving UKCA mark status, it intends to market to healthcare providers in the UK and internationally.

With UKCA mark status, Sensyne is now able to market SYNE-COV across the UK.  Sensyne will market the algorithm to NHS Trusts in order to help them with COVID preparedness and to deploy the algorithm in good time for the 2021/22 winter season.  

Dominic Conlin, Hospital Director, Chelsea and Westminster Hospital NHS Foundation Trust, said:

“We’re excited by the possibilities this offers.  This is individualised care by using patients’ own data to stratify risks and predict responses to clinical treatments, informing and supporting clinical decision making. This is a real step in taking forward digital innovation, data integration and analytics to enhance patient care in the NHS.”

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“This is the first Sensyne Clinical AI algorithm to achieve UKCA mark status that has been developed using our SENSE clinical AI platform.  The SENSE engine is expected to be able to generate clinical algorithms across a range of medical conditions that will provide real-time clinical decision making support. This is an important milestone for the Company and we look forward to being able to roll SYNE-COV out to the NHS.”